Tempest Historical Income Statement

TPST Stock  USD 6.34  0.04  0.63%   
Historical analysis of Tempest Therapeutics income statement accounts such as Interest Expense of 714.1 K, Selling General Administrative of 15.6 M, Cost Of Revenue of 369.6 K or Total Other Income Expense Net of 192.2 K can show how well Tempest Therapeutics performed in making a profits. Evaluating Tempest Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Tempest Therapeutics's future profits or losses.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Tempest Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tempest Therapeutics is a good buy for the upcoming year.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.

About Tempest Income Statement Analysis

Tempest Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Tempest Therapeutics shareholders. The income statement also shows Tempest investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Tempest Therapeutics Income Statement Chart

At this time, Tempest Therapeutics' Other Operating Expenses is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 15.6 M in 2025, whereas EBITDA is likely to drop (42.1 M) in 2025.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Tempest Therapeutics. It is also known as Tempest Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
Most accounts from Tempest Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Tempest Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.At this time, Tempest Therapeutics' Other Operating Expenses is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 15.6 M in 2025, whereas EBITDA is likely to drop (42.1 M) in 2025.

Tempest Therapeutics income statement Correlations

-0.990.7-0.770.99-0.78-0.780.710.270.86-0.750.770.09-0.03-0.560.110.040.05-0.040.03
-0.99-0.720.77-0.990.780.78-0.69-0.3-0.850.75-0.77-0.10.110.57-0.06-0.07-0.140.13-0.05
0.7-0.72-0.570.75-0.59-0.590.510.630.37-0.510.370.04-0.32-0.63-0.37-0.160.38-0.430.29
-0.770.77-0.57-0.761.01.0-0.42-0.06-0.870.99-0.540.560.00.55-0.22-0.16-0.01-0.020.07
0.99-0.990.75-0.76-0.77-0.770.680.320.84-0.740.730.1-0.09-0.560.060.050.12-0.120.05
-0.780.78-0.591.0-0.771.0-0.45-0.1-0.860.99-0.560.550.010.57-0.2-0.13-0.020.00.04
-0.780.78-0.591.0-0.771.0-0.45-0.09-0.860.99-0.560.550.00.57-0.2-0.13-0.020.00.04
0.71-0.690.51-0.420.68-0.45-0.450.550.54-0.430.90.190.22-0.64-0.12-0.37-0.11-0.080.28
0.27-0.30.63-0.060.32-0.1-0.090.55-0.06-0.020.290.26-0.48-0.67-0.73-0.710.55-0.690.7
0.86-0.850.37-0.870.84-0.86-0.860.54-0.06-0.890.72-0.250.14-0.390.440.22-0.150.2-0.19
-0.750.75-0.510.99-0.740.990.99-0.43-0.02-0.89-0.570.57-0.040.52-0.29-0.180.02-0.060.1
0.77-0.770.37-0.540.73-0.56-0.560.90.290.72-0.570.090.21-0.560.12-0.1-0.160.080.04
0.09-0.10.040.560.10.550.550.190.26-0.250.570.09-0.150.14-0.25-0.120.17-0.190.15
-0.030.11-0.320.0-0.090.010.00.22-0.480.14-0.040.21-0.150.230.550.16-0.940.78-0.45
-0.560.57-0.630.55-0.560.570.57-0.64-0.67-0.390.52-0.560.140.230.540.3-0.280.36-0.33
0.11-0.06-0.37-0.220.06-0.2-0.2-0.12-0.730.44-0.290.12-0.250.550.540.53-0.620.73-0.61
0.04-0.07-0.16-0.160.05-0.13-0.13-0.37-0.710.22-0.18-0.1-0.120.160.30.53-0.170.37-0.73
0.05-0.140.38-0.010.12-0.02-0.02-0.110.55-0.150.02-0.160.17-0.94-0.28-0.62-0.17-0.920.6
-0.040.13-0.43-0.02-0.120.00.0-0.08-0.690.2-0.060.08-0.190.780.360.730.37-0.92-0.73
0.03-0.050.290.070.050.040.040.280.7-0.190.10.040.15-0.45-0.33-0.61-0.730.6-0.73
Click cells to compare fundamentals

Tempest Therapeutics Account Relationship Matchups

Tempest Therapeutics income statement Accounts

202020212022202320242025 (projected)
Other Operating Expenses19.3M27.0M34.6M29.2M33.5M37.3M
Operating Income(19.3M)(27.0M)(34.6M)(29.2M)(42.0M)(44.1M)
Research Development14.4M17.2M22.5M17.5M28.1M19.0M
Ebitda(18.4M)(25.7M)(32.3M)(28.8M)(40.1M)(42.1M)
Total Operating Expenses19.3M27.0M34.6M28.8M42.0M37.2M
Income Before Tax(19.2M)(28.3M)(35.7M)(29.5M)(41.8M)(43.9M)
Net Income(19.1M)(28.3M)(35.7M)(29.5M)(41.8M)(43.9M)
Depreciation And Amortization815K1.3M1.8M381K389K369.6K
Interest Expense507K1.3M1.6M1.4M1.3M714.1K
Selling General Administrative4.9M9.8M12.1M11.7M13.6M15.6M
Ebit(19.2M)(27.0M)(34.1M)(29.2M)(40.5M)(42.6M)
Cost Of Revenue815K1.3M1.8M381K389K369.6K
Income Tax Expense(90K)1.2M1.1M(41.8M)(37.7M)(35.8M)
Gross Profit(815K)(1.3M)(1.8M)(381K)(342.9K)(325.8K)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.